Dosage & Reconstitution Guide
Tesamorelin Dosage & Reconstitution Guide
A clear educational guide covering Tesamorelin reconstitution, syringe unit conversions, protocol examples, supplies, storage, injection technique, GH/IGF-1 research notes and safety considerations.
Quickstart Highlights
- Peptide: Tesamorelin
- Common vial size: 10mg
- Example reconstitution: 3.0mL bacteriostatic water
- Resulting concentration: approximately 3.33mg/mL
- U-100 syringe maths: 1 unit = 0.01mL = approximately 33.3mcg
- Common protocol discussed: 1mg daily in Week 1, then 2mg daily from Week 2 onward
- Common cycle discussed: 12-26 weeks, with longer clinical monitoring contexts discussed
- Storage after mixing: refrigerate at 2-8°C and use within 7 days when mixed with bacteriostatic water
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, commonly abbreviated as GHRH. It works by stimulating the body’s own growth hormone release, which can increase IGF-1 levels.
In medical and research discussions, Tesamorelin is most commonly associated with visceral fat reduction, HIV-associated lipodystrophy, metabolic research, lipid profile changes, liver fat research and GH/IGF-1 pathway studies.
Tesamorelin Reconstitution Example
The example below is based on a common 10mg Tesamorelin vial mixed with 3.0mL bacteriostatic water.
Reconstitution Maths
10mg ÷ 3.0mL = 3.33mg/mL
3.33mg/mL = 3,333mcg/mL
1 unit on a U-100 syringe = 0.01mL
3,333mcg/mL × 0.01mL = approximately 33.3mcg per unit
Tesamorelin Unit Conversion Table
Standard Protocol Example
This example uses a 10mg vial reconstituted with 3.0mL bacteriostatic water, giving a concentration of approximately 3.33mg/mL.
Frequency and Timing Notes
Tesamorelin is commonly discussed as a once-daily subcutaneous compound. The source protocol describes evening administration as commonly preferred due to the relationship with nocturnal growth hormone release.
The practical points are consistency, accurate measurement, site rotation and medical monitoring where relevant, particularly for IGF-1 and blood glucose markers.
Reconstitution Steps
- Confirm the vial size before calculating concentration.
- Draw 3.0mL bacteriostatic water using sterile technique.
- Inject the bacteriostatic water slowly down the inside wall of the vial.
- Avoid blasting the powder directly and avoid creating foam.
- Gently swirl or roll the vial until dissolved.
- Do not shake.
- Label the vial with the reconstitution date and concentration.
- Store refrigerated at 2-8°C, protected from light.
- Use within 7 days when reconstituted with bacteriostatic water.
Supplies Needed
Tesamorelin Vials
- 8-week example: approximately 11 × 10mg vials.
- 12-week example: approximately 17 × 10mg vials.
- 16-week example: approximately 22 × 10mg vials.
Insulin Syringes
- Daily example: 7 syringes per week.
- 8 weeks: approximately 56 syringes.
- 12 weeks: approximately 84 syringes.
- 16 weeks: approximately 112 syringes.
Bacteriostatic Water
- Per 10mg vial: 3.0mL bacteriostatic water.
- 8-week example: 11 vials × 3.0mL = 33mL total, so 4 × 10mL bottles may be needed.
- 12-week example: 17 vials × 3.0mL = 51mL total, so 6 × 10mL bottles may be needed.
- 16-week example: 22 vials × 3.0mL = 66mL total, so 7 × 10mL bottles may be needed.
Alcohol Swabs
- Per administration: one swab for the vial stopper and one for the injection site.
- Per week: approximately 14 swabs based on daily administration.
- 8 weeks: around 112 swabs, so 2 × 100-count boxes may be needed.
- 12 weeks: around 168 swabs, so 2 × 100-count boxes may be needed.
- 16 weeks: around 224 swabs, so 3 × 100-count boxes may be needed.
Protocol Overview
- Goal discussed in research: visceral fat reduction, lipid profile changes and GH/IGF-1 pathway research.
- Schedule example: once-daily subcutaneous administration.
- Common amount discussed: 1mg daily in Week 1, then 2mg daily from Week 2 onward.
- Approximate weekly amount: around 14mg per week once at the 2mg daily amount.
- Example reconstitution: 3.0mL bacteriostatic water per 10mg vial.
- Concentration: approximately 3.33mg/mL.
- Cycle length: 12-26 weeks is commonly discussed, with longer clinical trial contexts requiring monitoring.
- Storage: lyophilised refrigerated, reconstituted refrigerated and not frozen after mixing.
Example Dosing Protocol
- Start: 1mg daily for Week 1 as a tolerability example.
- Standard example: 2mg daily from Week 2 onward.
- Frequency: once daily in the source protocol.
- Timing: evening administration is commonly discussed.
- Tracking: record date, amount, injection site and any observations.
How Tesamorelin Works
Tesamorelin mimics natural GHRH by binding to pituitary GHRH receptors. This can trigger pulsatile growth hormone secretion and subsequent IGF-1 elevation.
This GH/IGF-1 cascade is discussed in relation to lipolysis, protein synthesis and metabolic changes. In approved medical contexts, Tesamorelin has been used for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Research discussions also include potential effects on liver fat, metabolic health and cognitive function in older adults, although these contexts require careful interpretation and medical oversight.
Potential Benefits Discussed in Research
- Visceral adipose tissue reduction research
- HIV-associated lipodystrophy treatment context
- GH/IGF-1 pathway research
- Lipolysis and metabolic research
- Lipid profile research
- Potential liver fat research in NAFLD contexts
- Cognitive function research in older adults
- Body composition and endocrine pathway discussions
Reported Side Effects and Limitations
- Injection-site redness, itching, pain or bruising
- Joint pain or muscle aches
- Peripheral edema or mild swelling
- Carpal tunnel-type symptoms such as tingling or numbness
- IGF-1 elevation requiring monitoring
- Possible blood glucose or HbA1c changes in some patients
- Not suitable in pregnancy
- Not suitable for people with active malignancy or known hypersensitivity to tesamorelin or mannitol
Storage Instructions
- Lyophilised powder: commonly stored refrigerated at 2-8°C.
- After reconstitution with bacteriostatic water: refrigerate at 2-8°C.
- Use window: commonly discussed as within 7 days when mixed with bacteriostatic water.
- Sterile water note: if mixed with sterile water, some protocols state it should be used immediately.
- Do not freeze after mixing: avoid freezing reconstituted solution.
- Protect from light: keep the vial away from unnecessary light exposure.
- Avoid: heat, sunlight, moisture, contamination and repeated freeze-thaw cycles.
Injection Technique Notes
This section is general educational information only. It is not personal injection instruction.
- Use a new sterile insulin syringe for each administration.
- Clean the vial stopper and injection site with alcohol and allow both to dry completely.
- Common subcutaneous sites discussed include abdomen, thighs and upper arms.
- For abdomen use, avoid injecting too close to the navel.
- Rotate injection sites systematically to reduce local irritation and lipohypertrophy risk.
- Pinch a skinfold and insert into subcutaneous tissue at an appropriate angle.
- Inject slowly and steadily.
- Wait a few seconds before withdrawing the needle to help reduce leakage.
- Withdraw the needle at the same angle and apply gentle pressure if needed.
- Do not rub the site vigorously.
- Dispose of used sharps safely in a sharps container.
Lifestyle Factors That May Matter
- Nutrition: a balanced, protein-forward diet may support body composition and recovery goals.
- Training: resistance training and aerobic activity are often discussed alongside metabolic health goals.
- Sleep: 7-9 hours of quality sleep supports natural GH pulsatility and recovery.
- Stress management: stress reduction may support adherence, sleep and recovery.
- Tracking: documenting amount, date, site and observations can make tolerance patterns easier to review.
- Monitoring: IGF-1 and blood glucose monitoring may be relevant in clinical contexts.
Use the Peptide Calculator
If your vial size, water volume or target amount is different, use the Peptide Hub Australia calculator to work out concentration, mL and syringe units.
Calculate Tesamorelin Units
Enter your vial size, BAC water amount and target amount to calculate concentration and syringe units.
Open Peptide CalculatorWhere to Compare Tesamorelin Suppliers
Peptide Hub Australia does not sell Tesamorelin or any other peptides. We compare Australian peptide vendors, package audits, pricing and supplier information to help users review the market more clearly.
Frequently Asked Questions
How much BAC water do you add to a 10mg Tesamorelin vial?
A common educational example is 3.0mL bacteriostatic water added to a 10mg vial, creating a concentration of approximately 3.33mg/mL.
How many units is 1mg of Tesamorelin?
If a 10mg vial is mixed with 3.0mL, 1mg is approximately 30 units on a U-100 insulin syringe, equal to around 0.30mL.
How many units is 2mg of Tesamorelin?
If a 10mg vial is mixed with 3.0mL, 2mg is approximately 60 units on a U-100 insulin syringe, equal to around 0.60mL.
How long does one 10mg Tesamorelin vial last?
At 2mg daily, one 10mg vial contains around 5 administrations. At 1mg daily, it contains around 10 administrations, although the reconstituted storage window still matters.
When is Tesamorelin commonly discussed as being used?
The source protocol discusses once-daily administration, preferably in the evening, due to the relationship with nocturnal growth hormone release.
Is Tesamorelin the same as growth hormone?
No. Tesamorelin is a GHRH analogue that stimulates endogenous growth hormone release. It is not the same as injecting growth hormone directly.
Is Tesamorelin approved for medical use?
Tesamorelin is FDA-approved as a prescription medication for reducing visceral adipose tissue in HIV-associated lipodystrophy. This does not make it a general-use fat-loss compound.
Is this a personal dosing recommendation?
No. This page is an educational reconstitution and measurement guide only. It is not medical advice or a personal protocol.
